A phase 1/2 dose finding study of an experimental new drug CS7017, an oral PPARγ [peroxisome proliferators-activated receptor] agonist taken by mouth twice daily in combination with paclitaxel chemotherapy administered every three weeks by venous infusion by patients with anaplastic thyroid cancer.

Trial Profile

A phase 1/2 dose finding study of an experimental new drug CS7017, an oral PPARγ [peroxisome proliferators-activated receptor] agonist taken by mouth twice daily in combination with paclitaxel chemotherapy administered every three weeks by venous infusion by patients with anaplastic thyroid cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Efatutazone (Primary) ; Paclitaxel
  • Indications Thyroid cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 01 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 08 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 21 Nov 2009 Additional trial identifier (4274, SOL-08014-P) and additional trial centres identified as reported by Oregon Health and Science University Cancer Institute record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top